---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-016016"
form_type: "8-K"
ticker: "CYCN"
cik: "0001755237"
company_name: "Cyclerion Therapeutics, Inc."
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T02:11:36.434581+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cyclerion reports Q2 net loss $13.4M; positive CY6463 data in MELAS and CIAS studies

## Summary
- Cash $30.3M at June 30, 2022; net loss $13.4M vs $16.2M year ago.
- CY6463 showed improvements in biomarkers, cognitive performance, safety in MELAS and CIAS studies.
- Appointed Steven E. Hyman, M.D. to Board of Directors effective July 25, 2022.
- Enrollment ongoing in Phase 2a Alzheimer's disease with vascular pathology study; topline results expected 2023.
- R&D expenses $10.2M, G&A $3.5M; both down YoY.

## SEC filing metadata
- accession: 0000950170-22-016016
- form_type: 8-K
- ticker: CYCN
- cik: 0001755237
- company_name: Cyclerion Therapeutics, Inc.
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1755237/000095017022016016/0000950170-22-016016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1755237/000095017022016016/cycn-20220809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-016016
- JSON: https://secwatch.observer/filing/0000950170-22-016016.json
- Plain text: https://secwatch.observer/filing/0000950170-22-016016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.